RSS Agencia Europea de Medicamentos (EMA) | ¿Qué hay de nuevo Seguir Designación de medicamento huérfano: 2-[6-(6,7-Dimetoxiquinolin-3-il)piridin-3-il]-N-[3-(1,1,1-trifluoro-2-metilpropan-2-il)-1,2-oxazol-5-il]acetamida (zeteletinib) Tratamiento del carcinoma medular de tiroides, 19/02/2021 Retirado Orphan designation: 2-[6-(6,7-Dimethoxyquinolin-3-yl)pyridin-3-yl]-N-[3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-5-yl]acetamide (zeteletinib) Treatment of medullary thyroid carcinoma, 19/02/2021 Withdrawn ema.europa.eu
